Intravascular Large B-Cell Lymphoma: Clinical Trials

6 trials for Intravascular Large B-Cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 unknown, 1 recruiting, 1 suspended. 5 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Active not recruiting 2, Recruiting 1, Suspended 1, Unknown 1
Phase 11Suspended 1
Phase 31Active not recruiting 1

Follow Intravascular Large B-Cell Lymphoma: new trials by email Literature Review of Intravascular Large B-Cell Lymphoma trials Research Report on Intravascular Large B-Cell Lymphoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Cerebral Spinal Fluid ctDNA - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 2RecruitingMemorial Sloan Kettering Cancer Center502024-12-112025-12-18
A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types
No interventions need to be specified for this study - Lymphoma, Extranodal Lymphoma
UnknownRuijin Hospital100002023-07-012023-06-18
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma
Phase 2 / Phase 3Active not recruitingNational Cancer Institute (NCI)4222021-05-202026-11-12
Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma
Zanubrutinib, Rituximab, Cyclophosphamide - Intravascular Large B-Cell Lymphoma
Phase 2UnknownPeking Union Medical College Hospital202021-04-012021-05-24
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Nivolumab, Varlilumab - ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Phase 2Active not recruitingNational Cancer Institute (NCI)542018-12-212026-11-16
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab - Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma
Phase 1 / Phase 2SuspendedNorthwestern University302018-11-202022-08-15

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (4)  ·  Lymphoma, B-Cell (2)  ·  Lymphoma, B-Cell, Marginal Zone (2)  ·  Burkitt Lymphoma (1)  ·  Dendritic Cell Sarcoma, Interdigitating (1)  ·  Immunoblastic Lymphadenopathy (1)  ·  Lymphoma (1)  ·  Lymphoma, Extranodal NK-T-Cell (1)  ·  Lymphoma, Large-Cell, Anaplastic (1)  ·  Lymphoma, Primary Effusion (1)  ·  Lymphomatoid Granulomatosis (1)  ·  Plasmablastic Lymphoma (1)

Broader conditions

Hemic and Lymphatic Diseases (5)  ·  Immune System Diseases (5)  ·  Immunoproliferative Disorders (5)  ·  Lymphatic Diseases (5)  ·  Lymphoma, Non-Hodgkin (5)  ·  Lymphoproliferative Disorders (5)  ·  Neoplasms (5)  ·  Neoplasms by Histologic Type (5)  ·  Lymphoma (4)  ·  Lymphoma, B-Cell (3)  ·  DNA Virus Infections (1)  ·  Epstein-Barr Virus Infections (1)  ·  Herpesviridae Infections (1)  ·  Histiocytic Disorders, Malignant (1)  ·  Histiocytosis (1)

Interventions

Cyclophosphamide (3)  ·  Prednisone (3)  ·  Rituximab (3)  ·  CT-P10 (2)  ·  Doxorubicin (2)  ·  Nivolumab (2)  ·  Vincristine (2)  ·  deltacortene (2)  ·  prednylidene (2)  ·  Azacitidine (1)  ·  Disulfides (1)  ·  Epirubicin (1)  ·  Hyaluronoglucosaminidase (1)  ·  Immunoglobulin G (1)  ·  Magnetic Resonance Spectroscopy (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Northwestern University (1)  ·  Peking Union Medical College Hospital (1)  ·  Ruijin Hospital (1)

Countries

United States (4)  ·  China (2)

Top investigators

Daobin Zhou (1)  ·  Elizabeth A Brem (1)  ·  Jennifer Lue, MD (1)  ·  Reem Karmali, MD (1)  ·  Stephen M Ansell (1)

Results publications

PMID 34686472, PMID 40706069

NIH funding

P30CA060553 (1), U10CA180888 (1), UM1CA186686 (1), UM1CA186709 (1)